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The human parvovirus adeno-associated virus (AAV) infects a broad range of cell types, including human,
nonhuman primate, canine, murine, and avian. Although little is known about the initial events of virus
infection, AAV is currently being developed as a vector for human gene therapy. Using defined mutant CHO
cell lines and standard biochemical assays, we demonstrate that heparan sulfate proteoglycans mediate both
AAV attachment to and infection of target cells. Competition experiments using heparin, a soluble receptor
analog, demonstrated dose-dependent inhibition of AAV attachment and infection. Enzymatic removal of
heparan but not chondroitin sulfate moieties from the cell surface greatly reduced AAV attachment and
infectivity. Finally, mutant cell lines that do not produce heparan sulfate proteoglycans were significantly
impaired for both AAV binding and infection. This is the first report that proteoglycan has a role in cellular
attachment of a parvovirus. Together, these results demonstrate that membrane-associated heparan sulfate
proteoglycan serves as the viral receptor for AAV type 2, and provide an explanation for the broad host range
of AAV. Identification of heparan sulfate proteoglycan as a viral receptor should facilitate development of new
reagents for virus purification and provide critical information on the use of AAV as a gene therapy vector.
The primary event of any viral infection is attachment of
virus to the host cell. A wide variety of cell surface molecules
are now known to serve as viral attachment receptors. Such
receptors range from cell-specific transmembrane proteins of
well-defined receptor superfamilies (such as CD4 as a receptor
for human immunodeficiency virus [HIV]) (55) to the more
ubiquitous cell surface-associated carbohydrate moieties (such
as the common carbohydrate moiety sialic acid for influenza
virus) (23, 46). The mechanism by which adeno-associated
virus (AAV) attaches to its host cell has not been delineated.
A member of the Parvoviridae family, AAV is a small nonen-
veloped single-stranded DNA virus of 20 to 25 nm which has a
unique requirement for a helper virus (e.g., adenovirus [Ad] or
herpes simplex virus [HSV]) to complete its lytic cycle (2, 24,
39). In the absence of helper virus, AAV still infects the target
cell, but it integrates into the host genome and establishes
latency. Unique among eukaryotic DNA viruses, the AAV
genome can integrate site specifically into human chromosome
19 (21, 22, 30, 51, 54). This property has drawn considerable
attention to the potential use of AAV as a gene therapy vector
(36, 38, 50, 52). Despite this growing interest in AAV, the
events that govern the initial AAV infection remain poorly
understood.
Viral receptors are often involved in defining the host range
and specific tissue tropism of a virus. To date, among the 31
known eukaryotic parvoviruses, only one receptor, the eryth-
rocyte P antigen, which serves as the receptor for human par-
vovirus B19 (11), has been identified. Identification of the
receptor for B19 helps explain the tropism of this virus for
erythrocytes. Unlike human parvovirus B19, AAV has a very
broad host range and infects a wide variety of cell types, sug-
gesting that the virus uses a ubiquitous receptor to mediate
infection. Identification of the initial virus-host cell interac-
tions necessary for efficient AAV infection is important not
only for the general understanding of parvovirus infection but
also for the effective use of AAV as a gene therapy vector.
Although the initial events in the life cycle of AAV are not
well understood, previous studies suggest that AAV infects
cells through interaction with a specific host cellular receptor
(41, 45). AAV appears to exhibit saturation binding to HeLa
cells. In addition, cellular attachment of AAV is sensitive to
trypsin treatment, suggesting that a protein component is re-
sponsible for binding (41, 45). Further, AAV appears to bind
to a 150-kDa glycoprotein. Although AAV binds this glycopro-
tein in a viral overlay protein binding assay, the evidence that
the protein mediates virus binding to the cell surface remains
indirect (41). Here we provide both biochemical and genetic
evidence that cell surface heparan sulfate (HS) proteoglycan
serves as a receptor for AAV.
Proteoglycans are proteins classified by a posttranslational
attachment of polysaccharide glycosaminoglycan (GAG) moi-
eties each comprised of repeating disaccharide units (for re-
views see references 27 and 29). They can be found associated
with both the extracellular matrix and plasma membranes. The
four main widely distributed membrane-associated GAGs in-
clude heparin/HS and chondroitin sulfates A through C. These
unbranched sulfated GAGs are defined by the repeating di-
saccharide units that comprise their chains, by their specific
sites of sulfation, and by their susceptibility to bacterial en-
zymes known to cleave distinct GAG linkages (34). All have
various degrees of sulfation which result in a high density of
negative charge. Proteoglycans can be modified by more than
one type of GAG and have a diversity of functions, including
roles in cellular adhesion, differentiation, and growth. In ad-
dition, cell surface proteoglycans are known to act as cellular
receptors for some bacteria and several animal viruses (48),
including; foot-and-mouth disease type O virus (28), HSV
types 1 and 2 (57, 61), and dengue virus (12).
In this report, we identify HS proteoglycans as the primary
receptor for AAV. Our results show that cell surface HS
GAGs, and not other GAGs, serve as a principal attachment
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receptor for AAV type 2 (AAV-2). Further, our results indi-
cate that the presence of HS GAG on the cell surface directly
correlates with the efficiency by which AAV can infect cells.
MATERIALS AND METHODS
Reagents. The GAG lyases chondroitinase ABC, heparinase I, and heparinase
III (heparitinase) were purchased from Sigma. Chondroitinase AC was obtained
from Seikagagku America Inc. Soluble GAGs (heparin, from porcine intestinal
mucosa; chondroitin sulfate A, from bovine trachea; chondroitin sulfate B, from
porcine intestinal mucosa; and chondroitin sulfate C, from shark cartilage) were
purchased from Sigma.
Cells and virus. HeLa, CHO-K1, and CHO-K1 mutants deficient in proteo-
glycan biosynthesis were obtained from the American Type Culture Collection
(Rockville, Md.). HeLa cells were maintained in Dulbecco modified Eagle me-
dium (DMEM-H) supplemented with 10% fetal calf serum (FCS), and CHO
cells were grown in Ham’s F-12 medium supplemented with 10% FCS. Viruses
(wild-type [wt] AAV-2, recombinant AAV [rAAV]-LacZ, Ad dl309, and rAd-
LacZ) were prepared as previously described (53, 58). All virus preparations
were purified by two successive bandings on CsCl gradients to ensure purity.
Wild-type AAV particle numbers were determined by protein quantitation
(bicinchoninic acid reagent; Pierce), considering that the molecular mass of an
AAV virion is 4.5 3 106 g/mol. Recombinant virus titers were determined as
described previously (58). For preparation of radiolabeled wt AAV, 3 3 108
HeLa cells were infected with wt AAV and Ad dl309 at multiplicities of infection
(MOIs) of 10 and 5, respectively. [methyl-3H]thymidine (Amersham) was added
7 h postinfection to a final concentration of 1 mCi/ml (9). Labeled virus was
purified 48 h after infection as described above for wt AAV. 3H-AAV specific
activity was approximately 4.0 3 1028 cpm/virion. Fluorescent Cy3-labeled AAV-2
was a gift from Jeff Bartlett (Gene Therapy Center, University of North Carolina
at Chapel Hill).
Binding assays. All binding assays were done in a buffer which was determined
to result in maximum cell viability, HEPES-buffered saline (HBS) containing 1%
bovine serum albumin (HBSB; virus binding buffer). For direct binding assays,
3H-labeled wt AAV-2 was incubated with cells either attached to plates or in
suspension, as indicated, at a ratio of 4 3 1011 particles/3 3 105 cells for 90 min
at 4°C in HBSB. Cells were then washed three times in ice-cold HBSB to remove
unbound virus and solubilized in 0.3 N NaOH. After neutralization with glacial
acetic acid, cell-associated radioactivity was quantitated in a scintillation counter.
For inhibition studies and after enzymatic treatments, 3H-AAV was bound to
adherent HeLa cells. Binding to wt CHO and CHO cell mutants was done with
suspended cells. Cells were first detached with 10 mM EDTA and then washed
twice in phosphate-buffered saline (PBS) containing 8.8 mM CaCl2 and 0.5 mM
MgCl2 and once in HBSB before binding of 3H-AAV. Nonspecific binding was
determined in the presence of 100-fold excess unlabeled wt AAV (previously
dialyzed in HBS–10% glycerol). Binding of Cy3-labeled virus was done on wt
CHO and pgsA-745 cells grown on coverslips. After fixation in 4% paraformal-
dehyde for 20 min at room temperature, cells were mounted on slides, and bound
Cy3-labeled virus was detected by confocal microscopy. Images were obtained
with an argon-krypton laser at an excitation of 565 nm, a pinhole setting of 0.97,
a 585-nm dichroic reflector, and a 590-nm long-pass barrier filter, using a Bio-
Rad MRC-600 laser scanning attachment.
Viral infection assays. (i) Inhibition assay. rAAV-LacZ at an MOI of 2 was
incubated in DMEM-H in the presence or absence of indicated soluble GAGs at
1.0, 5.0, 10, 20, 30 mg/ml for 1 h at 37°C. For infection, rAAV-LacZ or the
virus-GAG mixture was incubated with 2 3 105 HeLa cells for 1 h at 37°C in a
5% CO2 chamber. To stop the adsorption process, cells were washed thoroughly
and overlaid with DMEM-H supplemented with 2% FCS. After 44 h, cells were
washed in PBS and lysed with 100 mM potassium phosphate (pH 7.8)–0.2%
Triton X-100. b-Galactosidase activity was then assayed by using a Galacto-Light
Plus kit (Tropix Inc.) as described by the manufacturer. Data was collected in a
luminometer within the linear range of the assay, and enzyme activity is ex-
pressed as relative light units (RLU)/microgram of protein. Each experimental
condition was assayed in duplicate, and independent experiments yielded similar
results. Preincubation studies were performed as described above except that
HeLa cells were incubated with or without indicated concentrations of heparin in
DMEM-H for 1 h at 37°C and washed thoroughly prior to rAAV-LacZ infection.
(ii) Enzymatic treatment. GAG lyases were reconstituted in PBS. For enzy-
matic digestion of cell surface GAGs, 3 3 104 HeLa cells were washed and
incubated with the indicated concentrations of GAG lyases in PBS containing
0.1% bovine serum albumin, 0.2% gelatin, and 0.1% glucose (digestion buffer)
for 1 h at 37°C in a 5% CO2 chamber. Cells were then washed four times with
digestion buffer and subjected to rAAV infection as described above. Prior to
use, each enzyme was tested for activity by a standard method used to determine
specific activity of GAG lyases except that enzyme activity was monitored under
the conditions used for digestion, PBS (pH 7.4) at 37°C (33). Cells remained
attached to the plate after all enzymatic treatments. Each experimental condition
was performed in triplicate. b-Galactosidase activity was assayed as described
above and is expressed in RLU. Enzyme concentrations are expressed in inter-
national units per milliliter (1 IU is equivalent to 600 Sigma units).
(iii) CHO cell infection and UV treatment. For UV treatment, 3 3 104 CHO
cells were washed, overlaid with PBS, and treated with UV irradiation (45 J/m2)
in a UV Stratalinker (Stratagene, La Jolla, Calif.) prior to rAAV infection (18).
rAAV infections, at an MOI of 10, for both UV-treated and non-UV-treated
CHO cells were performed as described above. b-Galactosidase activity is ex-
pressed as the average RLU from rAAV infections performed in triplicate.
RESULTS
AAV binding and infection are inhibited by soluble GAGs.
Several observations led us to postulate that AAV-2 may use
cell surface proteoglycans as a receptor. First, we demon-
strated that AAV-2 binds to a cellufine sulfate column (47a).
Other viruses known to interact with such columns bind to
negatively charged surface molecules (for example, several
members of the Herpesviridae family known to use HS proteo-
glycans as attachment receptors [1, 13, 40, 57, 61]). Second,
AAV can infect a wide variety of human, rodent, and simian
cell lines (8, 44), suggesting that it uses a ubiquitous cell sur-
face molecule for infection. Since proteoglycans are present on
numerous cell types and it appears that proteoglycans are
ubiquitously expressed throughout the animal kingdom (14,
29), we tested the possibility that AAV-2 uses cell surface pro-
teoglycans to mediate infection.
If AAV infection initiates through interaction with cell sur-
face proteoglycans, one or more of the major GAGs found on
membrane-associated proteoglycans should act as competitive
inhibitors of AAV infection and binding. To test this possibil-
ity, we performed competition experiments with several known
GAGs found on membranes. In this assay, we analyzed the
ability of soluble GAGs to inhibit rAAV-LacZ reporter gene
transduction in HeLa cells. Increasing concentrations of GAGs
were incubated with rAAV prior to adsorption to cells at 37°C
for 1 h. Cells were harvested 44 h postinfection and assayed for
b-galactosidase activity. Of the four GAGs tested, heparin, a
molecule chemically very similar to HS GAG, inhibited AAV
infection maximally and in a dose-dependent manner (Fig.
1A). Heparin concentrations as low as 5 mg/ml resulted in
nearly 100% inhibition. Chondroitin sulfate B, which shares
the most structural similarity to heparin/HS, exhibited 71%
inhibition at 30 mg/ml. In contrast, chondroitin sulfate A and
chondroitin sulfate C at concentrations of up to 30 mg/ml
exhibited no significant effect, with less than 20% inhibition.
The observed inhibition was specific for AAV since similar
studies showed no effect on infection with Ad, another nonen-
veloped DNA virus whose receptor is the coxsackievirus-Ad
receptor (CAR) (data not shown) (6).
To rule out the possibility that significant inhibition of AAV
infection by heparin was due to an induced cellular effect of
this molecule on HeLa cells, preincubation studies were per-
formed. HeLa cells were incubated with the indicated concen-
trations of heparin (Fig. 1B), washed extensively, and then
infected with rAAV as described above. Unlike competition
experiments, preincubation of HeLa cells with heparin had
little effect on the ability of rAAV to transduce cells (Fig. 1B).
While the presence of heparin (5 mg/ml) during viral adsorp-
tion demonstrated 100% inhibition (Fig. 1A), preincubation
demonstrated less than 20% inhibition at concentrations up to
20 mg/ml (Fig. 1B). These data suggest that heparin interacts
directly with AAV and inhibits an early event of viral infection.
To further examine the observed specificity and to deter-
mine whether GAGs were inhibiting binding of the AAV viri-
ons to the cell surface, 3H-labeled wt AAV was incubated with
GAGs at various concentrations. After incubation with cells,
the mixture was washed and cells were solubilized to quantify
bound virus. By this assay, heparin (5 mg/ml) inhibited 90% of
AAV binding (Fig. 2), correlating with rAAV transduction
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data (Fig. 1). Furthermore, chondroitin sulfate B (dermatan
sulfate; 30 mg/ml) inhibited binding by 51% (Fig. 2). As ex-
pected, chondroitin sulfates A and C at similar concentrations
did not significantly affect the ability of virus to bind to HeLa
cells, exhibiting no more than 20% inhibition. These data sug-
gest that heparin inhibits AAV infection by interfering with
virion binding to the cell surface, presumably by competing for
structurally related HS moieties.
Since heparin is known to be modified by more sulfate
groups and has a higher charge density than the chondroitin
sulfates (49), it was important to determine whether inhibition
reflected specificity or was simply a function of charge. We
examined the ability of a highly sulfated GAG analog, dextran
sulfate (molecular weight, 5,000), to act as a competitive in-
hibitor. At the maximum concentration, 30 mg/ml, the ob-
served inhibition by dextran sulfate was only 36% (Fig. 2),
indicating that more than charge ratio is responsible for the
inhibition of AAV by heparin and chondroitin sulfate B. To-
gether, the above data support the hypothesis that AAV binds
to cell surface proteoglycan, that this interaction is important
for a productive infection, and that AAV exhibits specificity for
particular GAG moieties.
AAV requires GAGs on the cell surface for infection. Since
some GAGs are known to bind to specific cell surface recep-
tors (27), the foregoing experiments could not completely rule
out competition for a common receptor as a mechanism for
inhibiting virus binding. To address this issue, we used enzymes
that are known to specifically digest the GAGs present on the
cell surface before assaying virus specific binding. Heparinase
I and heparitinase cleave distinct linkages found in HS. Chon-
droitinase ABC cleaves at a linkage found in all chondroitin
sulfates, including dermatan sulfate (chondroitin sulfate B),
and chondroitinase AC cleaves only chondroitin sulfates A and
C (33). All enzymes were tested prior to use for activity and
assayed under the conditions described in Materials and Meth-
ods. Subconfluent HeLa cells were treated with various con-
centrations of each enzyme and assessed for 3H-AAV binding.
Consistent with early experiments, enzymatic treatment with
either heparitinase or heparinase greatly reduced the ability of
virus to bind the cell surface: 73 or 66%, respectively, at the
maximum concentration of enzyme tested (Fig. 3A). Further,
chondroitinase ABC and chondroitinase AC treatment did not
result in any reduction of AAV binding to HeLa cells (Fig.
3A). These data indicate that HS proteoglycan mediates at-
tachment of AAV to the cell surface.
The fact that 10-fold more heparinase than heparitinase was
required to obtain similar reduction of AAV binding was likely
due to its known lower enzymatic activity under the conditions
used (33). Further, to ensure that protease contaminants were
not responsible for reduction in AAV binding, digestion in the
presence of soluble substrate was performed. Exogenous ad-
dition of soluble HS reversed the effect of heparitinase treat-
ment on AAV binding to HeLa cells (data not shown). There-
fore, specific removal of plasma membrane-associated HS
moieties results in a diminished ability of AAV to bind the cell
surface. It was unexpected that chondroitinase ABC did not
have any effect on AAV binding since the presence of soluble
chondroitin sulfate B (dermatan sulfate) was able to inhibit
AAV transduction and binding to HeLa cells, albeit much less
efficiently than heparin. The lack of reduction in binding after
enzymatic treatment with chondroitinase ABC suggests that
AAV does not efficiently bind to dermatan sulfate present on
the cell surface. It is possible that AAV exhibits an interaction
FIG. 1. Inhibition of AAV infection by various GAGs. (A) rAAV was incubated with the indicated concentrations of heparin (■), chondroitin sulfate B (dermatan
sulfate) (E), chondroitin sulfate A ({), or chondroitin sulfate C (‚) for 1 h at 37°C prior to a 1-h adsorption of the virus-GAG mixture to HeLa cells for infection.
b-Galactosidase activity was assayed 44 h postinfection by using a Galacto-Light Plus kit (Tropix Inc.) and measured in a luminometer. Each point represents the
average percent decrease in RLU per microgram of protein relative to the maximum level obtained in experiments without GAG. (B) HeLa cells were preincubated
with increasing concentrations of heparin at 37°C for 1 h. After thorough washing, cells were infected with rAAV as described above. Data points represent the average
percent maximum RLU/microgram of protein obtained without heparin preincubation.
FIG. 2. Soluble heparin inhibits binding of AAV to the cell surface. After
preincubation of 3H-labeled wt AAV-2 with increasing concentrations of the
indicated GAGs or the GAG analog dextran sulfate, labeled virus was adsorbed
to HeLa cells for 90 min at 4°C. Unbound virus was removed by three washes
with ice-cold binding buffer, and radioactivity was quantitated as described in
Materials and Methods. Data are represented as the average percent inhibition
relative to the counts per minute bound in the absence of soluble GAG.
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with chondroitin sulfate B (dermatan sulfate) only when it is
present in excess amounts in solution.
The above data ruled out the possibility that in the coincu-
bation experiments, soluble heparin and AAV were competing
for a similar receptor or that heparin was sterically hindering
binding to something other than membrane-associated GAGs.
Instead, the data suggest that AAV binds to cell surface pro-
teoglycan and further suggest that this interaction is specific for
HS, not chondroitin sulfate, moieties.
To demonstrate the biological relevance of AAV binding to
cell surface HS, we determined whether removal of HS moi-
eties rendered cells less susceptible to AAV infection. We
examined the ability of rAAV-LacZ to transduce HeLa cells
after treatment with various concentrations of heparitinase or
heparinase. rAAV transduction was reduced by 80% com-
pared to untreated control cells (Fig. 3B). Importantly, as little
as 0.425 mIU of heparitinase per ml resulted in up to 72%
reduction of AAV infection. Consistent with inefficient hepa-
rinase enzyme activity under these conditions, approximately
10-fold more enzyme was required for a similar reduction in
AAV transduction. The reduced susceptibility of HeLa cells to
AAV infection after enzymatic removal of membrane-associ-
ated HS GAG indicates a significant role for HS proteoglycan
in AAV infection.
Mutants of the GAG synthesis pathway inhibit AAV bind-
ing. CHO cell derivatives defective in GAG synthesis were
used to further define the requirement for HS moieties for
AAV infection. These mutant cell lines have defined deficien-
cies in the production of specific GAGs. Cell line pgsA-745
lacks xylosyltransferase, an enzyme necessary for the initiation
of all GAG synthesis, and does not produce detectable levels of
proteoglycans (16). Mutant pgsB-618 has a defect in the galac-
tosyltransferase I gene and makes about 15% of the normal
amount of proteoglycan synthesized by wt cells (15, 17). Cell
line pgsE-606 is partially deficient in HS N-sulfotransferase
and produces an undersulfated form of HS proteoglycan (4, 5).
Finally, mutant pgsD-677 has a single mutation that affects
both N-acetylglucosaminyltransferase and glucuronosyltrans-
ferase activities that are necessary for the polymerization of HS
disaccharide chains and does not synthesize any HS proteogly-
can. This mutant cell line also produces approximately three
times more chondroitin sulfate than wt cells (15, 31).
To assess AAV binding to wt and mutant CHO cell lines,
cells were incubated with Cy3-labeled virions or 3H-AAV-2 as
described in Materials and Methods. Bound 3H-labeled virus
was collected by centrifugation, and fluorescence virus was
visualized by confocal microscopy (Fig. 4). Although binding of
Cy3-AAV to wt CHO cells was easily detectable (Fig. 4A, I),
no significant virus binding to pgsA mutant CHO cells was
observed (Fig. 4A, II). These binding observations were quan-
tified by using 3H-AAV-2. Compared to wt CHO cells, there
were 7.0- and 6.4-fold reductions in AAV binding to cell lines
pgsA-745 and pgsD-677, respectively. The poor attachment of
AAV to the HS GAG deficient mutant cells pgsA and pgsD
(Fig. 4B) provides genetic data indicating that the presence of
HS proteoglycan is a principal requirement for AAV attach-
ment to the cell surface. Further, the inefficient binding to
pgsD-677 (HS GAG deficient and three times more chon-
droitin sulfates) demonstrates that AAV exhibits specificity for
heparan. The 4.6-fold reduction in AAV binding to pgsB-618
(15% of the level of wt proteoglycans) was slightly higher than
the binding to proteoglycan-deficient pgsA and pgsD cells.
This result correlates well with the 85% overall lower produc-
tion of GAGs by the pgsB-618 mutant cell line. Interestingly,
AAV binding to the mutant pgsE-606 cell line, which produces
an undersulfated form of HS, was also diminished, albeit to a
lesser extent (2.6-fold). Since the pgsE-606 cell line is partially
deficient in N-sulfotransferase, a reduction in AAV binding to
this cell line suggests that N-sulfation of HS may be an impor-
tant determinant influencing AAV attachment. The observed
differences in virus binding to wt and GAG-deficient cells was
specific for AAV, since no effect was observed when binding of
labeled Ad was used (data not shown).
Although the ability of AAV to bind all mutants was signif-
icantly diminished, each mutant still exhibited some binding as
assessed by 3H-AAV in the presence of a 100-fold excess of
unlabeled virus (Fig. 4B). This finding suggests that AAV may
bind to yet unidentified cell surface receptors present in low
abundance or that extremely low levels of HS GAG are present
on these mutant cells. The pgsA cells have a low level of
xylosyltransferase activity, which could result in residual pro-
teoglycan synthesis (16, 17).
Overall, these data indicate that the HS and not chondroitin
sulfate moieties of cell surface proteoglycans serve as attach-
FIG. 3. Effect of enzymatic digestion of cell surface GAGs on AAV binding and infection. (A) HeLa cells were treated with the indicated concentrations of the
GAG lyase heparitinase, heparinase I (■), heparinase I ({), chondroitinase ABC (E), or chondroitinase AC (‚) as described in Materials and Methods. After thorough
washing, the ability of AAV to bind the cell surface was assessed as described for Fig. 2. Data points represent the average percent reduction in AAV binding relative
to AAV binding obtained without enzymatic treatment. (B) HeLa cells were treated with heparitinase or heparinase I as described in Materials and Methods. After
thorough washing, rAAV was incubated with cells for a 1-h adsorption period at 37°C. Cells were harvested 44 h postinfection and assayed for b-galactosidase activity.
Results are graphed as the average percent reduction in AAV transduction relative to transduction observed in the absence of enzymatic treatment. Data points
represent the mean and standard deviation of experiments performed in triplicate.
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ment receptors for AAV. In addition, the diminished ability of
AAV to bind pgsE-606 (mutant with undersulfated HS GAGs)
suggests that the degree of sulfation of HS is an important
factor influencing binding of AAV to HS proteoglycan.
HS proteoglycan mediates AAV infection. The CHO cell
mutants defective in GAG synthesis were also used to provide
genetic evidence that HS proteoglycans are necessary for an
efficient AAV infection. As with the previous infection exper-
iments, we used an rAAV-LacZ vector that expresses b-galac-
tosidase to assess AAV-2 infectivity as described in Materials
and Methods. The lack of cell surface HS proteoglycan signif-
icantly impaired the ability of AAV to infect CHO cells (Fig.
5). Compared to AAV transduction of wt cells, there was
significant reduction in AAV transduction of pgsA and pgsD
cells (Fig. 5A). In addition to lacking HS proteoglycan on the
surface, the pgsD cells overproduce chondroitin sulfate pro-
teoglycans. The poor infection of this cell line further demon-
strates the specificity of AAV for cell surface heparan and not
chondroitin moieties. We observed a 10-fold reduction in AAV
transduction of pgsB cells, which produce 85% less proteogly-
can than wt cells. It is not clear why the pgsD cells are almost
completely refractory to AAV infection (Fig. 5A) when bind-
ing to this cell line is similar to that observed with pgsA. pgsD
cells that produce excess chondroitin sulfates may bind AAV
inefficiently through these substrates. However, this interaction
may not lead to a productive infection, an observation seen by
others (43). With the exception of the pgsD cell line, the
inefficient AAV transduction of the CHO cell mutants clearly
paralleled the reduced ability of AAV to bind the cell surface.
The above data indicate that infection by AAV is closely cou-
pled to the amount of AAV that can attach to the cell surface
and that this attachment is primarily mediated by HS proteo-
glycans. Finally, the pgsE cells that produce an undersulfated
form of HS proteoglycans supported AAV transduction but
with 1.4-fold reduction (Fig. 5), consistent with the previously
observed level of AAV binding (Fig. 4B).
A rate-limiting step in rAAV vector transduction is ineffi-
cient synthesis of second-strand copies from virion single-
stranded DNA genomes (18, 19, 36). To ensure that the ob-
served differences in AAV infection were a result of inefficient
AAV binding and not due to impaired second-strand synthesis,
we treated cells with UV, a technique known to overcome
inefficiencies at this step (18). When mutant cells were treated
with UV to maximize transgene expression, enhancement of
rAAV-LacZ transduction was observed (10-fold) but overall
AAV infections were similar to those of non-UV-treated cells
(Fig. 5B). Taken together, the results obtained with the CHO
cell mutants deficient in GAG synthesis provide genetic evi-
dence that HS proteoglycan mediates both attachment and
entry of AAV-2.
DISCUSSION
We have used defined mutant CHO cells defective in GAG
synthesis and standard biochemical assays to establish that
membrane-associated HS proteoglycan serves as a receptor for
AAV-2 and mediates both viral attachment to and subsequent
infection of target cells. We have shown that binding and
infection of cells by AAV is sensitive to (i) competitive inhi-
bition with heparin, a soluble receptor analog, (ii) enzymatic
removal of HS but not chondroitin sulfate moieties from the
cell surface, and (iii) genetic defects in the cellular pathway for
the production of HS. In addition, the use of mutant cell lines
provided genetic evidence that HS, and not chondroitin sul-
fate, proteoglycans are responsible for a productive AAV in-
fection. This is the first report of a role for proteoglycan in
cellular attachment of a parvovirus and provides an explana-
tion for the broad host range of AAV.
We have demonstrated that HS proteoglycan serves as a
principal attachment receptor for AAV-2. However, additional
factors could also participate in AAV host cell attachment.
Some viruses can use more than one distinct attachment re-
FIG. 4. HS proteoglycan serves as a primary attachment receptor for AAV-2.
Wild-type CHO-K1 cells and CHO-K1 mutants defective in proteoglycan syn-
thesis were assessed for the ability to bind AAV-2. Cell line pgsA-745 lacks HS
and chondroitin sulfate proteoglycans; pgsD-677 lacks HS proteoglycan and
produces a threefold excess of chondroitin sulfate proteoglycans; pgsB-618 pro-
duces 15% of normal proteoglycans; pgsE-606 produces an undersulfated form
of HS proteoglycan and normal levels of chondroitin sulfate proteoglycans. (A)
Cy3-labeled AAV-2 was bound to wt CHO cells (I) and the pgsA-745 mutant that
lacks proteoglycans (II) as described in Materials and Methods. Images were
captured by confocal microscopy. (B) Binding of 3H-AAV to parental and
mutant CHO cells. Binding assays were performed at 4°C in Eppendorf tubes. A
total of 3 3 105 cells were incubated with 4 3 1011 particles of 3H-AAV for 90
min in HBSB. After thorough washing, cells were pelleted and solubilized, and
radioactivity was quantitated as described in Materials and Methods. Nonspecific
binding was determined by parallel binding studies done in the presence of a
100-fold excess of unlabeled virus. Data represent the mean specific binding and
standard deviation obtained from experiments performed in triplicate.
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ceptor. For example, HIV uses CD4 as its main attachment
receptor but can also attach to glycolipid galactosyl ceramide
to mediate infection (10, 55). Further, Ad attachment to target
cells can be mediated by aMb2 integrin as well as CAR (6, 25).
Since removal of HS moieties from the cell surface did not
completely abolish AAV infectivity and AAV still exhibits
some specific binding to cell lines that do not produce HS
proteoglycans, it is possible that AAV attachment and infec-
tion can also be mediated by an as yet unidentified receptor,
albeit inefficiently.
While the inefficient binding and poor infection by AAV in
the absence of HS GAGs suggests that HS proteoglycan could
mediate both AAV attachment and entry, it remains to be
determined whether AAV attachment to HS proteoglycan is
sufficient for viral entry. For example, it is well established that
the initial interaction of HSV with its host cell is mediated
through HS proteoglycans (35, 57, 61) and that another sec-
ondary event is responsible for promoting entry (20). Recently,
a novel member of the tumor necrosis factor/nerve growth
factor receptor family was demonstrated to serve as a mediator
of HSV entry (42). In addition, Ad infection is initiated by
attachment to CAR (6) followed by subsequent interaction
with secondary receptors, identified as aV integrins, that are
known to facilitate virus internalization (60). On the other
hand, a large percentage of HS proteoglycans are known to
undergo endocytosis (26, 63) and could be involved in direct
AAV internalization. Such a mechanism of entry has been
described for other HS proteoglycan ligands, including basic
fibroblast growth factor and lipoprotein lipase (47, 56). AAV
may use either or both of these proposed mechanisms of entry.
Further, the possibility that a large functional multireceptor
complex is required for efficient AAV entry should not be
ruled out, since cell surface proteoglycans have been impli-
cated as members of multimeric complexes (7). That is, our
results show the HS proteoglycans are required for AAV in-
fection but do not address whether they are in fact sufficient.
The GAG structures can be complex, exhibiting a diversity
of disaccharide sequences with heterogeneous sulfation. Some
GAG ligands require the presence of a specific sugar sequence
for high affinity binding, as is the case for antithrombin, which
binds a distinct sequence present in heparin/HS (3, 32). In
addition, a recent report identified HS GAGs as a receptor for
the pathogenic RNA virus dengue virus. However, the virus
appears to require a highly sulfated form of HS GAG in order
to be infectious (12). Although we have not identified a specific
sugar sequence requirement for AAV binding, our data indi-
cate that AAV requires HS and not chondroitin sulfate moi-
eties. This conclusion is based on the inability of chondroiti-
nase ABC enzymatic digestion to inhibit AAV binding and
infection as well as the inability of AAV to appreciably bind
and infect mutant CHO cells that lack HS yet have an excess of
chondroitin sulfate proteoglycans. HS GAGs consist of repeat-
ing disaccharide units composed of alternating glucosamine
and hexuronic acid (either glucuronic acid or iduronic acid)
monsacharides. The chondroitin sulfate disaccharide units con-
tain a galactosamine monosacharide in place of glucosamine.
Chondroitin sulfate B (dermatan sulfate) is the only chon-
droitin that contains iduronic acid monosacharides that are
also found in HS GAGs. The specificity exhibited by AAV for
HS moieties demonstrates that AAV prefers an interaction
with a glucosamine-hexuronic acid backbone. Further, since
excess soluble dermatan sulfate could inhibit AAV binding and
infection, AAV may prefer a HS backbone that contains idu-
ronic acid.
Our data may indicate that multiple receptor molecules me-
diate AAV infection. In cases where the amount of cell-asso-
ciated HS GAG was reduced, either by enzymatic digestion or
in mutant cell lines, the reduction in AAV infection was more
sensitive than the reduction of AAV attachment. One possible
explanation is that the density of receptors, and thus the in-
creased probability of virus or HS proteoglycan interactions
with some other receptor molecule(s), may be an important
factor influencing AAV entry. It will be interesting to deter-
mine if the amount of cell surface HS proteoglycan influences
the ratio of internalized virus to bound virus. Alternatively,
another explanation for our results may be that AAV can
attach to a subset of surface molecules that are not capable of
mediating AAV infection.
Since the degree of HS sulfation affects the amount of AAV
that can bind the cell surface, there appears to be an important
charge component to the specific AAV-HS interaction. A ma-
jority of ligand-proteoglycan interactions are mediated by a
cluster of basic amino acids displayed by the ligand and the
high density of charge found on sulfated GAGs (27, 29). Until
the crystal structure of AAV-2 is determined, we cannot be
certain which basic residues are exposed to the virion surface,
nor can we address the noncolinear basic amino acids that may
be close in space in the intact virion. However, there is a high
FIG. 5. HS proteoglycan mediates AAV infection. (A) AAV infection of wt and mutant CHO cells deficient in proteoglycan synthesis (described in the legend to
Fig. 4). rAAV-LacZ virus was incubated with cells at an MOI of 10 for 1 h at 37°C. Cells were harvested 44 h postinfection and assayed for b-galactosidase activity.
Data represent the mean and standard deviation of triplicate experiments. (B) UV treatment of wild-type and mutant CHO cells and its effect on rAAV transduction.
Cells were treated with UV (45 J/m2) in a UV Stratalinker (Stratagene) prior to infection with rAAV-LacZ as described above. b-Galactosidase activity was measured
as described for non-UV-treated cells.
VOL. 72, 1998 HS PROTEOGLYCAN, VIRAL RECEPTOR, AND AAV-2 1443
density of positively charged amino acids within the first 170
residues of the VP1 capsid protein, including three strings of
basic amino acids (either K/RX4/5KKR or KX6RKR) that, if
exposed on the virion surface, could be involved in an ionic
interaction with the cell surface. It is also interesting that viral
mutants that map in this region are referred to as low-infec-
tious-particle mutants (44).
Recently, we have demonstrated long-term (1.5-year) gene
expression after direct rAAV injection into immunocompetent
mouse muscle and brain (37, 62). These data have provided
preclinical results suggesting that this viral delivery system may
provide an attractive alternative to other vectors. In fact,
rAAV has recently been tested in a clinical trial for gene
therapy of cystic fibrosis without any signs of toxicity of im-
mune complications (19a). Identification of the AAV receptor
should now help facilitate maximum use of this vector with
appropriate target cells (bone marrow stem cells, airway epi-
thelia cells, etc.). Fluorescence-activated cell sorting analysis of
various human cells has shown a correlation between HS
GAGs and virus binding consistent with this report (58a).
Identification of the AAV receptor should provide further
information concerning primary events involved in AAV infec-
tion and future development of this virus as a viral vector.
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